Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Carducci

Showing results (71-80 of 322) with videos related to

Pageof 33
Sort By:
European Journal of Cancer (Oxford, England : 1990)|October 25, 2011
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Peng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapyMilena Braga-Basaria, Adrian S Dobs, Denis C Muller, et al.
Psycho-Oncology|May 1, 2012
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practiceClaire F Snyder, Amanda L Blackford, Antonio C Wolff, et al.
Human Pathology|August 20, 2013
Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomasAlcides Chaux, Roula Albadine, Luciana Schultz, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
Journal of Geriatric Oncology|October 30, 2020
Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities?Ramy Sedhom, Pei-Lun Kuo, Arjun Gupta, et al.
Clinical Genitourinary Cancer|May 27, 2008
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapyLance K Lassiter, Mohan K Tummala, Maha H Hussain, et al.
BJU International|June 19, 2012
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancerJatinder Goyal, Philipp Nuhn, Peng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trialEli Rosenbaum, Marianna Zahurak, Victoria Sinibaldi, et al.
Biomedicines|February 27, 2026
Age- and Treatment-Related Patterns in Fatigue, Coping/Resilience, and Skeletal Muscle Bioenergetics (<sup>31</sup>P-MRS τPCr) in Cancer Survivors: Exploratory Pilot AnalysisNada Lukkahatai, Susan Grayson, Michael A Carducci, et al.
Pageof 33

Showing results (71-80 of 322) with videos related to

Sort By:
Pageof 33
European Journal of Cancer (Oxford, England : 1990)|October 25, 2011
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinomaDaniel Keizman, Maya Ish-Shalom, Peng Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapyMilena Braga-Basaria, Adrian S Dobs, Denis C Muller, et al.
Psycho-Oncology|May 1, 2012
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practiceClaire F Snyder, Amanda L Blackford, Antonio C Wolff, et al.
Human Pathology|August 20, 2013
Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomasAlcides Chaux, Roula Albadine, Luciana Schultz, et al.
Clinical Advances in Hematology & Oncology : H&O|June 12, 2026
Clinical applications of PARP inhibitors in breast, ovarian, and prostate cancer: current insights and future directionsLaura M Linville, Jenna V Canzoniero, Catherine H Marshall, et al.
Journal of Geriatric Oncology|October 30, 2020
Changes in the place of death for older adults with cancer: Reason to celebrate or a risk for unintended disparities?Ramy Sedhom, Pei-Lun Kuo, Arjun Gupta, et al.
Clinical Genitourinary Cancer|May 27, 2008
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapyLance K Lassiter, Mohan K Tummala, Maha H Hussain, et al.
BJU International|June 19, 2012
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancerJatinder Goyal, Philipp Nuhn, Peng Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trialEli Rosenbaum, Marianna Zahurak, Victoria Sinibaldi, et al.
Biomedicines|February 27, 2026
Age- and Treatment-Related Patterns in Fatigue, Coping/Resilience, and Skeletal Muscle Bioenergetics (<sup>31</sup>P-MRS τPCr) in Cancer Survivors: Exploratory Pilot AnalysisNada Lukkahatai, Susan Grayson, Michael A Carducci, et al.
Pageof 33